CFPA Home Page
QuickJump
 
               
Browse By Industry
 

Course offering number:0809-201

Course ID:
1887
Join Our
Mailing List
Email:


Analytical Methods Validation for FDA Compliance
September 8-10, 2008
Burlingame, CA

J. Mark Green, Ph.D.; Principal Investigator, Bristol-Myers Squibb Medical Imaging

J. Mark Green Ph.D. is Director of Pharmacy and Analytical Development at Bristol-Myers Squibb Medical Imaging. Dr. Green is responsible for the development, validation, and transfer of analytical methods for drug substances and drug products. He is also responsible for stability testing, analytical support of safety assessment studies, and the preparation of method-related sections of regulatory submissions. Dr. Green has over 20 years of experience in drug development, and previously worked for the DuPont and DuPont Merck Pharmaceutical Companies. He has published and lectured on analytical method validation, and on applications of HPLC, TLC, and Chiral Chromatography. Dr. Green received his Ph.D. in Analytical Chemistry from the University of Illinois.

David E. Wiggins; Associate Director of Analytical/Stability R&D, Schering-Plough Consumer Health Care Products

David E. Wiggins is Associate Director of Analytical/Stability R&D for Schering-Plough Consumer Health Care Products. Since joining the company in 1982, Mr. Wiggins has worked in both Quality Control and Research and Development with responsibility for Method Optimization, Method Validation, Method Transfer and Stability (both pre- and post-market). These responsibilities have additionally included involvement with every NDA submission and every FDA inspection of the division since 1991.

Mr. Wiggins has over 25 years experience in the pharmaceutical industry in both a QC and an R&D setting. During this time, he has been instrumental in establishing and updating method validation policy to be consistent with the changing regulatory requirements. Mr. Wiggins has frequently lectured on analytical method validation principles in the US, Puerto Rico, and throughout Europe. He has been active in submitting comments and validated methods to the U.S. Pharmacopeia and has been an invited speaker to FDA, university, and industry conferences.